Biotech Values

[mcbio]

I'm debating whether I should get back into FOLD. If only it had options.

I wonder if it makes sense to wait until after the pivotal monotherapy data. I normally hate pivotal binary events anyways and there seems to some skepticism around the outcome and otherwise the size of the market (e.g., as you note GSK giving up rights to U.S. market). But, if negative and stock tanks, maybe get in for the combo opportunity down the road?